Alpha Tau to Present at Jefferies Global Healthcare Conference

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), an Israeli oncology therapeutics company, will be represented by CFO Raphi Levy at the Jefferies Global Healthcare Conference on June 5, 2025, from 1:25 to 1:55 PM ET in New York City. The presentation will highlight Alpha Tau's innovative cancer treatment approach using its flagship product, Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), which targets solid tumors through a novel alpha-radiation therapy.

Founded in 2016, Alpha Tau was established to focus on the research, development, and commercialization of Alpha DaRT, a cutting-edge therapeutic technique that delivers concentrated alpha radiation directly into tumors. The technology, which was developed by Professors Itzhak Kelson and Yona Keisari at Tel Aviv University, utilizes radium-224 sources that emit high-energy alpha particles. This method is designed to maximize the destruction of tumor cells while minimizing damage to surrounding healthy tissues, making it a potentially game-changing treatment in oncology.

During the conference, Mr. Levy will provide insights into the company's advancements and strategic initiatives regarding Alpha DaRT, while also engaging in one-on-one meetings with investors. Interested parties are encouraged to contact their Jefferies representative to arrange these discussions.

Alpha Tau Medical represents an exciting convergence of innovative science and potential market impact, with its technology poised to redefine treatment approaches for patients with solid tumors. The upcoming presentation at the Jefferies Global Healthcare Conference is a pivotal opportunity for the company to showcase its advancements and to connect with potential investors keen on the future of cancer treatment. For further information or investor inquiries, Alpha Tau can be contacted via email at IR@alphatau.com.

As Alpha Tau Medical Ltd. prepares to present at the Jefferies Global Healthcare Conference on June 5, 2025, investors should closely evaluate the potential implications of its alpha-radiation cancer therapy, Alpha DaRT ®. The presentation, scheduled to be delivered by CFO Raphi Levy, offers a pivotal opportunity for the company to highlight advancements in its innovative treatment approach for solid tumors, characterized by localized efficacy and reduced collateral damage to surrounding healthy tissues.

Alpha Tau, founded in 2016, operates in a niche yet increasingly competitive oncology market. With the backdrop of rising healthcare costs and a growing incidence of cancer, novel therapies like Alpha DaRT hold substantial appeal to both investors and healthcare professionals. The efficacy demonstrated in preclinical trials positions Alpha DaRT as a promising alternative to conventional radiation therapies, potentially capturing market share as healthcare systems seek more effective oncology solutions.

Investors attending the conference may want to focus on key aspects of the presentation, particularly any updates on clinical trial results, regulatory milestones, and partnerships. Success in these areas could significantly bolster Alpha Tau's stock performance and market perception. Furthermore, the opportunity for one-on-one meetings with Levy could provide deeper insights into the company's strategic direction and financial health, critical for evaluating investment risks and opportunities.

Given the complexities of drug development and market dynamics, it is crucial for investors to remain vigilant about external factors such as competing therapies, regulatory challenges, and market adoption rates. While the potential of Alpha DaRT is compelling, prudent financial analysis should weigh both the promise of innovation against the inherent risks in the biotechnology sector. Investors may consider maintaining a diversified portfolio while closely monitoring Alpha Tau's upcoming developments for potential entry points or adjustments in investment strategies.